Cargando…

Optimization of single dose VSV-based COVID-19 vaccination in hamsters

Mostrar otras versiones (1)

The ongoing COVID-19 pandemic has resulted in global effects on human health, economic stability, and social norms. The emergence of viral variants raises concerns about the efficacy of existing vaccines and highlights the continued need the for the development of efficient, fast-acting, and cost-ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Donnell, Kyle L., Clancy, Chad S., Griffin, Amanda J., Shifflett, Kyle, Gourdine, Tylisha, Thomas, Tina, Long, Carrie M., Furuyama, Wakako, Marzi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437312/ https://www.ncbi.nlm.nih.gov/pubmed/34518839 http://dx.doi.org/10.1101/2021.09.03.458735

Ejemplares similares

Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model
por: O'Donnell, Kyle L., et al.
Publicado: (2021)

Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model
por: O’Donnell, Kyle L., et al.
Publicado: (2021)

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine
por: Furuyama, Wakako, et al.
Publicado: (2021)

Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine
por: Furuyama, Wakako, et al.
Publicado: (2022)

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine
por: O'Donnell, Kyle L., et al.
Publicado: (2023)

The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway
por: Furuyama, Wakako, et al.
Publicado: (2021)

Single-dose VSV-based vaccine protects cynomolgus macaques from disease after Taï Forest virus infection
por: Fletcher, Paige, et al.
Publicado: (2023)

Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease
por: Marzi, Andrea, et al.
Publicado: (2021)

Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus
por: Prator, Cecilia A., et al.
Publicado: (2023)

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern
por: Griffin, Amanda J., et al.
Publicado: (2021)

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern
por: Griffin, Amanda J., et al.
Publicado: (2022)

Marburg virus pathogenesis – differences and similarities in humans and animal models
por: Shifflett, Kyle, et al.
Publicado: (2019)

Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge
por: Marzi, Andrea, et al.
Publicado: (2019)

Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection
por: Furuyama, Wakako, et al.
Publicado: (2020)

Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates
por: Bhatia, Bharti, et al.
Publicado: (2023)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection
por: Menicucci, Andrea R., et al.
Publicado: (2019)

Histopathologic Characterization of Experimental Peracute SARS-CoV-2 Infection in the Syrian Hamster
por: Clancy, Chad S., et al.
Publicado: (2023)

Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
por: O’Donnell, Kyle L, et al.
Publicado: (2021)

Multidimensional sample analysis to determine pandemic viral evolution
por: O'Donnell, Kyle L., et al.
Publicado: (2023)

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
por: Malherbe, Delphine C., et al.
Publicado: (2021)

A VSV-based Zika virus vaccine protects mice from lethal challenge
por: Emanuel, Jackson, et al.
Publicado: (2018)

The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
por: Suder, Ellen, et al.
Publicado: (2018)

Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs
por: Madar-Balakirski, Noa, et al.
Publicado: (2022)

A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades
por: Furuyama, Wakako, et al.
Publicado: (2020)

Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV(MT)) in golden syrian hamster
por: Ke, Yong, et al.
Publicado: (2023)

A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection
por: Furuyama, Wakako, et al.
Publicado: (2020)

Ebola Virus Glycoprotein Domains Associated with Protective Efficacy
por: Bhatia, Bharti, et al.
Publicado: (2021)

Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
por: Wright, KJ, et al.
Publicado: (2012)

Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation
por: Marzi, Andrea, et al.
Publicado: (2019)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
por: Sorvillo, Teresa E., et al.
Publicado: (2021)

Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans
por: Poetsch, Joseph H, et al.
Publicado: (2019)

Monitoring Group Activity of Hamsters and Mice as a Novel Tool to Evaluate COVID-19 Progression, Convalescence, and rVSV-ΔG-Spike Vaccination Efficacy
por: Melamed, Sharon, et al.
Publicado: (2021)

Titration methods for rVSV-based vaccine manufacturing
por: Gélinas, Jean-François, et al.
Publicado: (2020)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
por: Santoro, Francesco, et al.
Publicado: (2021)

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
por: Cook, Joselle, et al.
Publicado: (2022)

Long-Term Single-Dose Efficacy of a Vesicular Stomatitis Virus-Based Andes Virus Vaccine in Syrian Hamsters
por: Prescott, Joseph, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1jbkt0m9ekish7u5opv0msturs